Contrasting Biomerica (NASDAQ:BMRA) & Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) and Biomerica (NASDAQ:BMRA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Boston Scientific and Biomerica, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2	8	20	1	2.65
Biomerica	1	0	0	0	1.00

Boston Scientific currently has a consensus target price of $61.43, suggesting a potential upside of 38.59%. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 561.76%. Given Biomerica’s higher possible upside, analysts plainly believe Biomerica is more favorable than Boston Scientific.

Volatility & Risk

Boston Scientific has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation & Earnings

This table compares Boston Scientific and Biomerica”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07 billion	3.20	$2.90 billion	$2.36	18.78
Biomerica	$4.45 million	0.94	-$3.78 million	($1.64)	-0.83

Boston Scientific has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Boston Scientific and Biomerica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Boston Scientific	16.62%	18.61%	10.58%
Biomerica	-115.50%	-142.81%	-77.83%

Institutional and Insider Ownership

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 12.3% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Boston Scientific beats Biomerica on 13 of the 15 factors compared between the two stocks.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

About Biomerica

Biomerica, Inc. is a medical diagnostics company that develops, manufactures and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. Its offerings are intended for use by physicians, laboratories and consumers, depending on the product. The company’s principal product is inFoods IBS, a blood-based diagnostic and therapeutic system designed to identify foods that may contribute to symptoms associated with irritable bowel syndrome. The system is intended to support a personalized dietary program under the direction of a healthcare professional.